The biotech mailbag: Your questions answered on Clovis Oncology, CytRx, Brainstorm Therapeutics, and more
The Biotech Stock Mailbag has a new home. Here’s what readers are saying:
Steve N. writes, “I don’t understand why people are selling Clovis Oncology on this news of a partnership with Bristol-Myers Squibb? Can you explain what I am missing here?”
Clovis, which fell 14 percent Monday, got caught up in one of those counter-intuitive, only-on-Wall-Street situations where good news is treated like bad news because it’s not the good news people expected.
The news reported Monday: Clovis and Bristol are pairing up to conduct combination studies of Rubraca (Clovis’ and Opdivo (Bristol’s checkpoint inhibitor) in ovarian cancer, triple-negative breast cancer, and prostate cancers. Financial terms were not disclosed but this appears to
You’re reading a preview, subscribe to read more.
Start your free 30 days